Why Is Harmony Biosciences (HRMY) Up 12.1% Since Last Earnings Report?
Harmony Biosciences (HRMY) stock rose 12.1% since last earnings. The company expects multiple clinical trial data in 2026-2027, including for pitolisant GR and epilepsy treatments. HRMY reaffirmed 2026 revenue guidance of $1B-$1.04B, with Q2 revenues up 21% sequentially. Analysts have upwardly revised estimates, and HRMY has an aggregate VGM Score of A.
How this was made
The 30-second read
Why it matters
Regulatory acceptance and guidance reaffirmation suggest a stable near‑term outlook with upside potential.
Market read
The news provides fresh regulatory and guidance data that can influence HRMY's stock price and sector sentiment.
What to watch
Potential competition in narcolepsy and rare disease space could limit market share.
Background
Harmony Biosciences provides narcolepsy treatment Wakix and is expanding pitolisant into rare neurological disorders.
Ticker impact
FDA accepted the new drug application for pitolisant GR with a target action date of April 1, 2027, and the company reaffirmed its 2026 revenue guidance.
potential upside as market prices in reduced regulatory uncertainty
The acceptance is a primary disclosure for a biotech, indicating a clear path to market and reinforcing guidance, which traders can act on.
Market effects
Strengthens the narcolepsy and rare disease biotech sector by showing FDA progress.
U.S. biotech investors may increase exposure to HRMY and similar pipelines.
Limited to companies with FDA-regulated products; modest global effect.
Counterpoint
If the upcoming data disappoint, the earlier regulatory win may be priced out.
Key entities
- companyHarmony Biosciences Holdings, Inc.
Biotech firm developing pitolisant and epilepsy assets.
- regulatorFDA
U.S. Food and Drug Administration that accepted the NDA.
